LEVEMIR (insulin detemir) by Novo Nordisk. Approved for insulin analog [epc]. First approved in 2005.
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
Levemir (insulin detemir) is a long-acting basal insulin analog administered subcutaneously for the management of diabetes mellitus. It provides steady, peakless insulin coverage over 24 hours, reducing blood glucose levels in patients requiring insulin therapy. The drug mimics the body's basal insulin secretion to maintain glycemic control between meals and overnight.
With LOE approaching and moderate Part D spending of $287M in 2023, Levemir teams are transitioning from growth initiatives to lifecycle extension and market defense strategies.
Insulin Analog
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study of All-Cause and Cardiovascular Mortality in Type 2 Diabetes Patients Using Basal Insulin Detemir and Glargine
Research Study Comparing Insulin Degludec to Insulin Detemir, Together With Insulin Aspart, in Pregnant Women With Type 1 Diabetes
A Trial Investigating the Efficacy and Safety of Insulin Detemir Versus Insulin NPH in Combination With Metformin and Diet/Exercise in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on Metformin With or Without Other Oral Antidiabetic Drug(s) With or Without Basal Insulin
A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
Worked on LEVEMIR at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo$287M Medicare spend — this is a commercially significant brand
Working on Levemir in 2024 places you in a mature asset entering LOE phase; career value lies in defensive commercial strategy, payer negotiation, and biosimilar preparation rather than growth launches. Roles emphasize market access, health economics, and competitive positioning as the product transitions toward generic/biosimilar competition.